Positively charged RGD-lipid-Protamine nanoparticles with diameters of 222 nm were used to deliver siRNA targeted against PAX3-FOXO1 (P3F), a fusion transcript expressed in alveolar rhabdomyosarcoma (ARMS) [99]. Here, FOXO1 is linked to alveolar rhabdomyosarcoma.